Growth Hormone Secretagogues Compared: Which GHS Do Researchers Choose?

Growth hormone secretagogues (GHS) are among the most widely studied peptide classes in endocrine research. These compounds stimulate growth hormone (GH) release from the anterior pituitary, but they do so through different receptors, different mechanisms, and with markedly different side effect profiles. For researchers designing studies involving the GH/IGF-1 axis, choosing the right secretagogue is not a trivial decision — it shapes everything from the kinetics of GH release to the secondary hormonal effects you will need to account for.

This guide compares seven of the most commonly studied growth hormone secretagogues: GHRP-2, GHRP-6, Hexarelin, Ipamorelin, Sermorelin, Tesamorelin, and CJC-1295. We will cover how each one works, what distinguishes it from the others, and which research contexts favor each compound. A comprehensive comparison table is included for quick reference.

Two Families, Two Receptors

Before diving into individual compounds, it helps to understand that growth hormone secretagogues fall into two broad families based on their receptor targets:

GHRH Analogs (Growth Hormone-Releasing Hormone Pathway)

These peptides mimic or extend the action of endogenous GHRH, binding to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary. This pathway represents the physiological “on switch” for GH secretion. Compounds in this family include:

• Sermorelin — a truncated GHRH analog (first 29 amino acids)
• Tesamorelin — a modified GHRH analog with enhanced stability
• CJC-1295 — a GHRH analog with Drug Affinity Complex (DAC) for extended half-life

Growth Hormone-Releasing Peptides (Ghrelin/GHS-R Pathway)

These synthetic peptides bind to the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor that responds to the endogenous hunger hormone ghrelin. This represents a separate, complementary pathway to GH release. Compounds include:

• GHRP-2 — the most potent hexapeptide GHS
• GHRP-6 — the original synthetic GHS hexapeptide
• Hexarelin — a super-analog of GHRP-6 with additional receptor binding
• Ipamorelin — the first selective GHS (GH release without ACTH/cortisol stimulation)

Understanding which family a compound belongs to is the first step in selecting the right tool for your research question. GHRH analogs work with the body’s natural GH pulse generator. GHRPs amplify GH release through an independent pathway and can produce GH release even when GHRH signaling is suppressed.

The GHRH Analog Family

Sermorelin (GRF 1-29)

Sermorelin is a 29-amino acid peptide corresponding to the first 29 residues of endogenous 44-amino acid GHRH. It is the shortest synthetic peptide that retains full biological activity at the GHRH receptor. Sermorelin was FDA-approved in the 1990s for diagnostic testing and treatment of growth hormone deficiency in children, giving it one of the longest clinical track records among GHS compounds.

Mechanism: Sermorelin binds the GHRH-R on anterior pituitary somatotrophs, stimulating both the release of stored GH and the transcription of new GH mRNA. This dual effect — immediate release plus increased production — distinguishes GHRH pathway compounds from GHRPs, which primarily trigger release of existing GH stores.

Key advantage: Because sermorelin works through the physiological GHRH pathway, it preserves the natural pulsatile pattern of GH secretion and maintains negative feedback through somatostatin and IGF-1. This has led researchers to characterize it as a more “physiological” approach to GH stimulation compared to exogenous GH administration.

Limitations: Sermorelin has a short half-life (approximately 10-20 minutes), requiring frequent administration. Its GH-releasing potency is moderate compared to the GHRPs, and it is less effective in elderly subjects where GHRH-R expression may be reduced.

Full research coverage: Sermorelin Research Guide

Tesamorelin (Egrifta)

Tesamorelin is a synthetic analog of GHRH with a trans-3-hexenoic acid modification that enhances stability and receptor binding. It is the only GHS with current FDA approval — specifically for reduction of excess abdominal fat in patients with HIV-associated lipodystrophy (marketed as Egrifta).

Mechanism: Like sermorelin, tesamorelin binds the GHRH-R and stimulates endogenous GH synthesis and release. The structural modification provides improved resistance to enzymatic degradation, resulting in greater bioavailability compared to unmodified GHRH or sermorelin.

Clinical data: Phase III clinical trials demonstrated that subcutaneous tesamorelin significantly decreased visceral adipose tissue (VAT) and waist circumference after 26 weeks of daily administration. The compound also decreased muscle fat and increased muscle area. However, the effect on VAT was not sustained after discontinuation — patients switched to placebo demonstrated re-accumulation of visceral fat to near baseline levels.

Safety note: Despite the expected physiological regulation through IGF-1 feedback, clinical trials showed that tesamorelin recipients were more likely to have IGF-1 levels above the upper limit of normal and were more likely to develop diabetes compared to placebo.

Full research coverage: Tesamorelin Research Guide

CJC-1295 (with DAC)

CJC-1295 is a tetrasubstituted form of GRF(1-29) — meaning it starts with the same 29-amino acid framework as sermorelin but includes four amino acid substitutions plus a Drug Affinity Complex (DAC). The DAC is a maleimide derivative that covalently binds to endogenous albumin after subcutaneous injection, dramatically extending the peptide’s half-life.

Mechanism: CJC-1295 activates the GHRH-R identically to sermorelin and tesamorelin. The critical difference is pharmacokinetic: while sermorelin has a half-life of minutes, CJC-1295 with DAC has an estimated half-life of 5.8-8.1 days. This means a single injection produces sustained GH elevation for nearly a week.

Efficacy data: In healthy adults, a single injection of CJC-1295 produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and in mean plasma IGF-1 concentrations by 1.5- to 3-fold for 9-11 days. Importantly, pulsatile GH secretion was maintained during continuous stimulation, confirming that the somatostatin feedback loop remained functional.

Research considerations: The extended half-life of CJC-1295 is a double-edged sword. It reduces injection frequency dramatically, but it also means that if adverse effects occur, they cannot be rapidly reversed by stopping administration. For time-course studies requiring precise control of GH exposure, shorter-acting GHRH analogs may be preferable.

Full research coverage: CJC-1295/Ipamorelin Research Guide

The GHRP Family

GHRP-6

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) holds a special place in GHS history — it was the first synthetic peptide that specifically elicited dose-dependent GH release both in vitro and in vivo. Developed in the 1980s by Cyril Bowers’ laboratory, GHRP-6 launched an entire field of research into non-GHRH-mediated GH secretion.

Mechanism: GHRP-6 binds GHS-R1a on pituitary somatotrophs, triggering GH release through a pathway independent of and additive to GHRH signaling. The GHS-R1a receptor signals through phospholipase C and intracellular calcium mobilization, a mechanism distinct from the cAMP-mediated signaling of the GHRH-R.

Non-GH effects: GHRP-6 is notable for its significant non-GH endocrine effects. It stimulates appetite through ghrelin receptor activation, increases ACTH and cortisol secretion, and elevates prolactin levels. These off-target effects are important for researchers to account for in study design — a GHRP-6-treated group is not only experiencing elevated GH but also elevated cortisol and altered appetite signaling.

Research utility: Despite (or because of) its broad receptor activity, GHRP-6 remains valuable for studies examining GHS-R1a biology, appetite regulation, and the interaction between GH and stress hormone axes.

Full research coverage: GHRP-6 Research Guide

GHRP-2

GHRP-2 (D-Ala-D-betaNal-Ala-Trp-D-Phe-Lys-NH2) was developed as a more potent successor to GHRP-6. It remains one of the strongest GH-releasing peptides available for research, producing robust dose-dependent GH secretion that exceeds the response to GHRH alone.

Mechanism: GHRP-2 stimulates GH release from pituitary cells through the same GHS-R1a receptor as GHRP-6. Despite structural differences between the peptides, receptor binding studies have confirmed they share the same receptor and signaling mechanism.

Potency: In direct comparisons, 1 microgram/kg GHRP-2 induced a strong GH response comparable to hexarelin and significantly higher than the response to GHRH at the same dose. GHRP-2 is generally considered the most potent GHRP in terms of raw GH release per unit dose.

Side effects: Like GHRP-6, GHRP-2 stimulates ACTH and cortisol release. It also produces a modest increase in prolactin levels. The appetite-stimulating effect is present but generally less pronounced than with GHRP-6.

Full research coverage: GHRP-2 Research Guide

Hexarelin

Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GHS that was designed as a “super-analog” of GHRP-6 with enhanced GH-releasing potency. It is notable for having the highest GH-releasing activity of the classical hexapeptide GHS compounds.

Mechanism: Hexarelin binds both GHS-R1a and CD36, a scavenger receptor involved in fatty acid transport and macrophage function. This dual-receptor activity sets hexarelin apart from other GHRPs and has led to research on its cardioprotective properties independent of GH release.

Potency and tachyphylaxis: While hexarelin produces the strongest acute GH response among the GHRPs, it is also the most susceptible to tachyphylaxis (reduced response with repeated dosing). Studies in rats showed that repeated doses of hexarelin led to progressive attenuation of GH release, a significant consideration for chronic study designs.

Cardioprotective research: The CD36-binding activity of hexarelin has prompted research into cardiac applications independent of GH. Studies have explored hexarelin’s effects on cardiac fibrosis, ischemia-reperfusion injury, and cardiac remodeling — effects mediated through CD36 rather than GHS-R1a.

Full research coverage: Hexarelin Research Guide

Ipamorelin

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) occupies a unique position among GHRPs: it was the first growth hormone secretagogue identified as truly selective for GH release. While GHRP-2, GHRP-6, and hexarelin all stimulate ACTH, cortisol, and prolactin alongside GH, ipamorelin produces GH release with minimal effects on these other hormones.

Mechanism: Ipamorelin is a pentapeptide that selectively binds GHS-R1a. In conscious swine models, ipamorelin released GH with an ED50 of 2.3 nmol/kg. Crucially, at GH-maximally effective doses, ipamorelin did not release ACTH, cortisol, prolactin, or aldosterone — making it the cleanest GHS for studies requiring isolated GH effects.

Selectivity advantage: The selectivity of ipamorelin is its primary research advantage. In studies where cortisol elevation would confound GH-related endpoints (body composition, glucose metabolism, immune function), ipamorelin allows researchers to isolate GH effects from stress hormone contamination.

GI motility research: Beyond GH release, ipamorelin has been investigated as a treatment for postoperative ileus (impaired gut motility after surgery). A rodent model study demonstrated that ipamorelin improved gastric motility, suggesting potential applications beyond endocrine research.

Full research coverage: CJC-1295/Ipamorelin Research Guide

Head-to-Head Comparison Table

Compound	Family	Receptor	Half-Life	GH Potency	ACTH/Cortisol	Prolactin	Appetite	Tachyphylaxis Risk
Sermorelin	GHRH analog	GHRH-R	10-20 min	Moderate	No	No	No	Low
Tesamorelin	GHRH analog	GHRH-R	26-38 min	Moderate-High	No	No	No	Low
CJC-1295 (DAC)	GHRH analog	GHRH-R	5.8-8.1 days	High (sustained)	No	No	No	Low
GHRP-6	GHRP	GHS-R1a	~20 min	High	Yes (significant)	Yes (moderate)	Yes (strong)	Moderate
GHRP-2	GHRP	GHS-R1a	~25 min	Very High	Yes (significant)	Yes (mild)	Yes (moderate)	Moderate
Hexarelin	GHRP	GHS-R1a + CD36	~70 min	Highest (acute)	Yes (moderate)	Yes (moderate)	Mild	High
Ipamorelin	GHRP	GHS-R1a	~2 hours	Moderate-High	No	No	Mild	Low

Which GHS for Which Research Question?

Choosing the right secretagogue depends entirely on the research question. Here is a decision framework based on common study designs:

Isolated GH Effects on Body Composition or Metabolism

Best choice: Ipamorelin — Its selectivity means observed effects can be attributed to GH/IGF-1 without cortisol or prolactin confounds. CJC-1295 is a good alternative when sustained GH elevation is desired.

Maximum Acute GH Stimulation

Best choice: GHRP-2 or Hexarelin — Both produce robust acute GH peaks. GHRP-2 is preferred for repeated-dose protocols due to hexarelin’s tachyphylaxis risk.

Physiological GH Pulsatility Studies

Best choice: Sermorelin — Preserves natural GH pulse patterns and somatostatin feedback. The short half-life allows precise timing of GH pulses.

Sustained GH Elevation (Days)

Best choice: CJC-1295 (with DAC) — The albumin-binding DAC technology provides 6+ days of elevated GH from a single administration.

GH + Appetite/Ghrelin Pathway Research

Best choice: GHRP-6 — The strongest appetite stimulation among GHRPs makes it ideal for studies examining ghrelin receptor-mediated feeding behavior alongside GH effects.

Cardioprotection Research (GH-independent)

Best choice: Hexarelin — Its unique CD36 binding provides cardioprotective effects that can be studied independently of GH release.

Clinical Translation Studies

Best choice: Tesamorelin — As the only currently FDA-approved GHS, it has the most extensive human safety and efficacy data.

GHRH + GHRP Synergy Studies

Best combination: CJC-1295 + Ipamorelin — The combination of GHRH-R and GHS-R1a stimulation produces synergistic GH release greater than either pathway alone. Ipamorelin’s selectivity keeps the combination cleaner than GHRP-2 or GHRP-6 pairings. This is one of the most commonly studied GHS combinations in the literature.

GHRH + GHRP Synergy: Why Researchers Combine Pathways

One of the most significant findings in GHS research is that GHRH pathway and GHRP pathway compounds produce synergistic — not merely additive — GH release when combined. This makes biological sense: GHRH primarily increases GH synthesis and primes somatotrophs for release, while GHRPs primarily trigger the release of stored GH through an independent signaling cascade.

Research by Bowers and others demonstrated that the combination of GHRH + GHRP consistently produces GH release that exceeds the sum of individual responses. This synergy has been confirmed across multiple GHRH/GHRP combinations and across species, establishing it as a robust pharmacological principle rather than a compound-specific phenomenon.

The practical implication for researchers is that lower doses of each compound can achieve the same GH response as higher doses of either alone, potentially reducing off-target effects while maintaining the desired GH endpoint.

Safety and Tolerability Across Compounds

While all GHS compounds have been generally well-tolerated in published studies, several safety considerations vary by compound:

• IGF-1 elevation: All GHS compounds increase IGF-1 as a downstream effect of GH release. Tesamorelin clinical trials showed IGF-1 levels above the upper limit of normal in some subjects, and an increased incidence of diabetes in treated vs. placebo groups.
• Cortisol/ACTH effects: GHRP-2, GHRP-6, and hexarelin all stimulate the HPA axis. In studies requiring cortisol monitoring, this necessitates additional controls and biomarker tracking.
• Tachyphylaxis: Hexarelin is the most prone to diminishing response with repeated dosing. Continuous infusion studies showed progressive attenuation of GH release. Study designs using hexarelin should account for this with washout periods or dose escalation protocols.
• Injection site reactions: Reported across all compounds but most systematically documented in tesamorelin clinical trials, where they were the most common adverse event.
• Duration of exposure: CJC-1295’s extended half-life means that any adverse effects persist for days after the last injection — an important safety consideration for study monitoring protocols.

Practical Laboratory Considerations

For researchers working with these compounds, several practical factors deserve attention:

• Reconstitution: All GHS peptides should be reconstituted in bacteriostatic water according to manufacturer specifications. Reconstituted solutions should be stored at 2-8 degrees C.
• Timing of blood draws: GH peaks occur at different times post-administration depending on the compound. GHRP-mediated peaks typically occur within 15-30 minutes, sermorelin peaks at 15-45 minutes, and CJC-1295 peaks are more sustained. Blood sampling protocols should be adjusted accordingly.
• Fasting status: Glucose and free fatty acid levels influence GH response to secretagogues. Standardizing nutritional status across subjects is essential for reproducible results.
• Gender and age effects: GH response to secretagogues varies by sex and age. Female subjects typically show higher GH responses to GHRPs, while responses to all GHS compounds decline with age.

Summary of Key Research References

Study	Year	Type	Focus	Reference
Sigalos & Pastuszak	2018	Review	Safety and efficacy of growth hormone secretagogues	PMC5632578
Sinha et al.	2020	Review	GHS role in body composition management	PMC7108996
Walker et al.	2006	Review	Sermorelin for adult-onset GH insufficiency	PMC2699646
Stanley & Bhatt	2012	Review	Tesamorelin for HIV lipodystrophy	PMC3218714
Fourman & Mantzoros	2019	Clinical	Tesamorelin decreases muscle fat in HIV	PMC6766405
Teichman et al.	2006	Clinical	CJC-1295 prolonged GH/IGF-1 stimulation in healthy adults	PMID 16352683
Ionescu & Bhatt	2006	Clinical	Pulsatile GH secretion persists during CJC-1295 stimulation	PMID 17018654
Berlanga-Acosta et al.	2017	Review	Synthetic GHRPs: cytoprotective effects	PMC5392015
Raun et al.	1998	In vivo	Ipamorelin — first selective growth hormone secretagogue	PMID 9849822
Arvat et al.	1997	Clinical	GHRP-2 vs hexarelin vs GHRH: GH, ACTH, cortisol comparison	PMID 9285939

Written by NorthPeptide Research Team

---

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research. It does not constitute medical advice, treatment recommendations, or an endorsement for any therapeutic purpose. The research discussed herein is predominantly preclinical, and results may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving these compounds.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes.